Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn

SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA

@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i

No need to stop Tofa w/the flu? 👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB. 👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar. Abstr#L04 #ACR20 @rheumnow #ACRBest https://t.co/rZXKRVl7uK

• Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitin…

@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012) 📍Limitations: small number of pts https://t.co/zeLzrNLeDQ

SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA 1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks 2⃣Similar improvement in UPA 15mg vs. 30mg 3⃣Both doses similar or > Adalimumab @RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0

Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1

• https://meet.acrconvergence.org/meetings/virtual/wtv3TtGdj9h5scjeN

#ACR20👀🔥🔥@AliDuarteMD Population epi revealed: ⭐️Markedly increased SLE incidence ⭐️Drastically increased SLE prevalence Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk